Cost-effectiveness treatment with Rituximab in patients with rheumatoid arthritis in real life

Rheumatology International

Volumn 31, Issue 11, 2011, Pages 1465-1469

  Benucci, Maurizio ^a   Saviola, Gianantonio ^b   Baiardi, Paola ^b   Manfredi, Mariangela ^c  

^a Ospedale di S Giovanni di Dio   (Italy)

^b IRCCS   (Italy)

^c SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

Author keywords

Cost effectiveness; Rheumatoid arthritis; Rituximab

Indexed keywords

RITUXIMAB;

AGED; ARTICLE; CLINICAL ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; HUMAN; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RHEUMATOID ARTHRITIS;

AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COST-BENEFIT ANALYSIS; DRUG COSTS; FEMALE; HEALTH STATUS; HUMANS; JOINTS; MALE; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY-ADJUSTED LIFE YEARS; RECOVERY OF FUNCTION;

EID: 83555163944     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-010-1502-6     Document Type: Article

References (20)

1. F Salaffi R De Angelis W Grassi MArche Pain Prevalence; Investigation Group (MAPPING) study 2005 Prevalence of musculoskeletal conditions in an Italian population sample: results of a regional community-based study. I. The MAPPING study Clin Exp Rheumatol 23 6 819 828 16396700 1:STN:280: DC%2BD28%2FhsFCnsg%3D%3D (Pubitemid 43040510)
2. G Leardini F Salaffi R Montanelli S Gerzeli B Canesi 2002 A multicenter cost-of-illness study on rheumatoid arthritis in Italy Clin Exp Rheumatol 20 4 505 515 12175106 1:STN:280:DC%2BD38vitVyjsA%3D%3D (Pubitemid 34846625)
3. G Kobelt L Johnsson P Lindgren A Young K Eberhardt 2002 Modeling the progression of rheumatoid arthritis. A two-country model to estimate costs and consequences RA Arthritis Rheum 46 2310 2319 12355478 10.1002/art.10471
4. J Fries P Spitz R Kraines H Holman 1980 Measurement of patient outcome in arthritis Arthritis Rheum 23 137 145 7362664 10.1002/art.1780230202 1:STN:280:DyaL3c7ltlGlsQ%3D%3D (Pubitemid 10164318)
5. G Torrance 1986 Measurement of health state utilities for economic appraisal. A review J Health Econ 5 1 30 10311607 10.1016/0167-6296(86)90020-2 1:STN:280:DyaL283otVOltQ%3D%3D (Pubitemid 16098443)
6. G Kobelt K Eberhardt P Geborek 2004 TNF-inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow-up study of patients with RA treated with etanercept or infliximab in southern Sweden Ann Rheum Dis 63 4 10 14672883 10.1136/ard.2003.010629 1:CAS:528:DC%2BD2cXotlOiuw%3D%3D (Pubitemid 38064595)
7. SB Cohen P Emery MW Greenwald, et al. 2006 Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy Arthritis Rheum 54 2793 2806 16947627 10.1002/art.22025 1:CAS:528:DC%2BD28XhtFWksLjI (Pubitemid 44497758)
8. NJ Bansback A Brennan O Ghatnekar 2005 Cost-effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden Ann Rheum Dis 64 7 995 1002 15550533 10.1136/ard.2004.027565 1:STN:280:DC%2BD2MzhtVKgsw%3D%3D (Pubitemid 40909512)
9. M Benucci F Li Gobbi L Sabadini G Saviola P Baiardi M Manfredi 2009 The economic burden of biological therapy in rheumatoid arthritis in clinical practice. Cost-effectiveness analysis in Italian patients treated with sub-cutaneous anti-TNFα Int J Immunopathol Pharmacol 4 1147 1152
10. A Kielhorn P Duncan A Diamantoupoulos L Gavin 2008 UK cost-utility of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic disease modifying antirheumatic drug Curr Med Res Opin 24 2639 2650 18687164 10.1185/03007990802321683 1:CAS:528:DC%2BD1cXhtlKit7vO
11. P Lindgren P Geborek G Kobelt 2009 Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden Int J Technol Assess Health Care 25 181 189 19331709 10.1017/S0266462309090230
12. R Launois S Payet N Saidenberg-Kermanac C Francesconi L Riou Franc MC Boissier 2008 Budget impact model of rituximab after failure of one or more TNFa inhibitor therapies in the treatment of rheumatoid arthritis Joint Bone Spine 65 288 295
13. Benucci M, Iannazzo S, Zaniolo O, Sabadini L (2010) Rituximab in the treatment of rheumatoid arthritis patients in Italy: a budget impact analysis. Clin Exp Rheumatol (in press)
14. TA Hallinen EJ Soini K Eklund K Puolakka 2010 Cost-utility of different treatment strategies after the failure of tumor necrosis factor inhibitor in rheumatoid arthritis in the Finnish setting Rheumatology 4 767 777 10.1093/rheumatology/kep425
15. L Jacobsson Y Lindroth L Marsal 2007 Rheumatoid arthritis: what does it cost and what factors are driving those costs? Results of survey in a community-derived population in Malmo, Sweden Scand J Rheumatol 36 179 183 17657670 10.1080/03009740601089580 1:STN:280:DC%2BD2svjvFShsw%3D%3D (Pubitemid 47174541)
16. E Keystone 2006 Switching tumor necrosis factor inhibitors: an opinion Nat Clin Pract Rheumatol 35 415 425
17. R Van Vallenhoven H Hariu S Brennemark L Klareskog 2003 Treatment with infliximab when etanercept has failed or vice versa: data from the STURE registry showing that switching tumor necrosis factor alpha blockers can make sense Ann Rheum Dis 62 1195 1198 10.1136/ard.2003.009589 (Pubitemid 37500626)
18. A Finckh A Ciurea L Brulhart 2007 B cells depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents Arthritis Rheum 56 1417 1423 17469098 10.1002/art.22520 (Pubitemid 46764068)
19. P Geborek T Saxne 2000 Clinical protocol for monitoring of targeted therapies in rheumatoid arthritis Rheumatology 39 1159 1161 11035144 10.1093/rheumatology/39.10.1159 1:STN:280:DC%2BD3M%2FjtlKmsw%3D%3D
20. JA Karlson LE Kristensen MC Kapaetanovic 2008 Treatment response to a second or third TNF inhibitor in RA: results from South Swedish Arthritis Treatment Group Register Rheumatology 47 507 513 10.1093/rheumatology/ken034